Nat. Volatiles & Essent. Oils, 2021; 8(5): 900 - 904

NVEO
Natural Volatiles & Essential Oils

Case Report on T-Cell ALL (Acute Lymphoblastic Leukemia)

Mr. Pratik Omprakash Malviya[1], Ms. Priyanka S. Meshram[2], Aniket Pathade[3] , Nita Rehapade[4]

1 GNM 2nd year, Florence Nightingale training college of nursing, Sawangi(m)Wardha; Email:- pratikmalviya321@gmail.com ; Mobile number: - 8657491065

2 Nursing Tutor, Florence Nightingale Training College of Nursing, Sawangi meghe, Wardha; Email: priyankameshramganvir@gmail.com; Mobile No. 8600289201

3 Research Consultant, Jawaharlal Nehru Medical College, Datta Meghe Institute Of Medical Sciences , Wardha.

4 Dept. of Electronics & Tele. Engineering, Yeshwantrao Chavan College of Engineering, Nagpur. Email: nitamnimbarte@rediffmail.com

ABSTRACT: -

Introduction- T-cells, also known as T-lymphocytes, are a type of leukocyte (white blood cell) that helps the immune system. T-lymphocytes are one of two types of lymphocytes, the other being B lymphocytes. T cells mature in the thymus and multiply after being created in the bone marrow. Cytokines are chemical messengers secreted by helper T cells that stimulate the development of B cells into plasma cells. This was a case of T cell acute lymphoblastic leukaemia . **Main symptoms and important clinical findings-** The patient admitted the hospital with complaint of fever, loss of appetite, vomiting with blood tinged food particles and malaria since from 1-2months. **The main diagnosis, therapeutic intervention and outcomes:** Chemotherapy is the best method to treatment to leukemia. Medical management was provided to the patient, Injection calcium gluconate, Injection Pantop, tablet Septran, tablets Limcee, tablet Paracetamol, Zinc power, Inj. ondansetron, Syp. Duphalac. **Conclusion**: Acute lymphoblastic leukaemia (ALL) affects both children and adults, however it is most common between the ages of 2 and 5. ALL is thought to be caused by a combination of factors, including external and endogenous exposures, genetic predisposition, and chance. The rate of paediatric cancer survivorship

Keywords: T -cell , Acute lymphoblastic leukaemia, Loss of appetite.

INTRODUCTION:

Adult acute lymphoblastic leukaemia (ALL) affects roughly one in 100,000 people each year. In contrast to childhood ALL, when overall survival is over 80% at 5 years,[1] treatment progress has been modest, with an average survival rate of 35% in patients aged 18 to 60. According to a recent assessment, there was a 14 percent to 20% rise in age-dependent survival from 2000 to 2004 when compared to 1980 to 1984.[2] Because of the vast clinic prognostic variability, ALL necessitates a sophisticated and highly diversified treatment. Newer clinical trials should aim to boost survival rates closer to 50% and set the way for further progress. To this purpose, the ideas of risk-oriented and tailored therapy must be fully developed. ALL affects lymphocyte progenitor cells in the bone marrow, blood, and haematogenous tissues. Adults are at risk of death, despite the fact that children account for 80% of all cases. ALL is expected to affect 1.6 persons in every 100,000 people in the United States.

Acute lymphoblastic leukaemia (ALL) can afflict both children and adults, however it is most frequent in children aged two to five. A variety of factors, including external and endogenous exposures, genetic predisposition, and chance, are thought to be responsible for ALL. The percentage of children who survive.

Recent research has found that risk stratification based on biologic characteristics of white blood cells and responsiveness to therapy, pharmacological adjustments based on the patient pharmacodynamics and personalized medicine, and enhanced supportive therapy have boosted the survival rate of ALL to over 90%. New techniques, on the other hand, are required to increase survival while lowering negative consequences. While the majority of kids can be treated, the prognosis for neonates and adults with acute lymphocytic leukemia is bleak. New structural genetic changes and sequence abnormalities that contribute to the growth of acute lymphoblastic leukaemia, define new acute lymphocytic leukaemia subtypes, influence treatment responsiveness, Through genetic code analysis of germline and leukemic cell DNA, researchers have uncovered new prognostic markers and therapeutic targets for personalized therapy.[3]

Patient information:

Patient specific information:-A 15 year's old male child admitted in AVBR hospital with chief complaint of fever, loss of appetite, vomiting with blood tinged food particles and malaria since from 1-2months. Presently case visited/reported in AVBRH in old base on date with complaint of fever, loss of appetite, vomiting with blood tinged food particles and malaria since from 1-2 months, There is no any past medical history. Patient belongs to nuclear family and his family is belongs to middle class family, He was mentally stable, he is well oriented with time, place, and person, he is maintained good relationship with family members , community people's.

Primary concern and synonymous of patient:-

Patient visited in A.V. B .R hospital in OPD based on date 01/05/2021 with chief complaint of loss of appetite, fever, blood in vomiting with tinged food particles from 1-2month.

Medical, family, and psychosocial:-

The present case was seen at the AVBRH on June 22, 2021, with the main complaint being oedema in the lower jaw. Medical, familial, and psychosocial history were all taken. There history of family related to the brachial cleft fistula. He belonged to joined family and her husband had medical history of Hypertension. He was mentally stable, conscious and oriented to date, time and place. He had maintained good relationship with doctors and nurses as well as other patients also. His father breadwinner of his family and him work as a farmer.

Relevant past intervention with outcomes: - Present case had medical history. The patient was taken to GMC Hospital Nagpur with a major complaint of lack of appetite and fever, and he was diagnosed with malaria within 1-2 months of his admission. Patient's general condition was poor at the time, He was stable after receiving treatment.

Significant physical examination and important clinical finding:-

There are no high-risk signs or symptoms on physical examination. However, there are some common complaints, such as lack of appetite, fever, and blood in vomiting with coloured food particles. These signs and symptoms are reported in the majority of patients, and they are often repeated. After the lumber

puncture procedure, the patient was diagnosed with everything. Candidate voluntarily consented to an excision under general anaesthesia, which was scheduled for a later date.

Timeline:-

The current instance had a history of fever, lack of appetite, blood in his vomit, coloured food particles, and malaria, and he was seen in April 2021 at GMC hospital for treatment. The patient's illness was discovered through a lumber puncture, and he was subsequently referred to the AVBR facility for additional treatment. Patient was visited in AVBR hospital on OPD base with chief complaint of fever, loss of appetite, blood in vomiting with tinged food particles and malaria Further management.

Diagnostic assessment:-

On the basis of patient history, physical examination, blood investigation and other investigations the patient diagnosed T cell all (acute lymphoblastic leukemia). The blood test sample report as Hb % 9.7gm and total RBC is 4.41 and WBC count 20200 and total platelet count 2.74. x ray was done. Blood sugar was normal but Haemoglobin level was decrease. Urea serum was slightly decreased. Total WBC count was increased. Blood pressure was 110/70 mmhg. No challenges experienced during diagnostic evaluation.

Therapeutic intervention:-

First, the patient was treated with the VDCLP plan for one cycle. Chemotherapy has a satisfactory result, and then he received continuous treatment and was currently in good condition, Tablet Limcee, Tablet Paracetamol, Syrup Ascoril-D, Syrup Gelusil.

Follow up and outcomes:-

Clinical and patient assessed outcome:-

Despite all of the patient's care, the patient's health will improve more than before. After taking care of the current regular medicine and eating a healthy diet, the patient's health will improve more than before.

Important follow up diagnostic and other test result:-

All signs and synonyms, such as loss of appetite, fever, and weakness, can change.

They have no trouble in losing their hunger as a result of physiological changes.

DISCUSSION:-

Although one-third of adult patients with acute lymphoblastic leukaemia can be cured, outcomes vary substantially due to differences in clinical, immunologic, and cytogenetic/genetic features. These statistics, combined with the kinetics of early therapeutic efficacy, aid in the accurate identification of an individual's risk category and the development of risk-specific treatments it should result in perfect outcomes with the lowest non-relapse mortality achievable. Quality and high chemotherapy (increasingly based on paediatric principles), through genetic code analysis of germline and leukemic cell DNA, researchers have uncovered new prognostic markers and targeted therapies for personalized therapy.

These adjustments are improving long-term outcomes, which are predicted to be close to 50% or higher in ongoing trials[3].

Due to various contemporary multiagent treatment, event-free survival (EFS) rates for children with acute lymphocytic leukemia (ALL) have improved dramatically during the preceding four decades. In high-income countries with the best-accessible rehabilitation services, overall survival is now above 90%. Asparaginase therapy is a critical component of these therapies. Asparaginase has been on the WHO's list of essential medicines since 1978.[4,5] However, it has been linked to a number of side effects that could lead to therapy inactivation, modification, or termination. Multiple childhood acute lymphocytic leukaemia studies have connected failure to finish the specified course of asparaginase therapy to decreased cure rates.[6,7,8] As a result, standards are needed to guarantee that patients receive the whole therapy course. At the International Society for Neonatal Oncology's Congress in Lyon in October 2019, an expert panel discussed strategies for maintaining active asparaginase treatment, such as therapeutic drug monitoring (TDM) for determining dietary activity levels and premedication to avoid infusion related responses (IRRs), as well as attempting to avoid medical hypersensitivity, silent inhibition, and other adverse effects[9]. A number of studies on related aspects of leukemia were reported[10-15].

The National Comprehensive Cancer Network has created risk stratification recommendations based as to what is known about prognostic variables in adults with acute lymphocytic leukaemia. 16 Adolescents and young adults (AYA) are defined as individuals between the ages of 15 and 39, according to the NCCN. Teenagers and young adults, according to the NCCN, may benefit from treatment with paediatric-inspired regimens, and are thus handled differently than people over the age of 40.[9] After that, High-risk Ph-positive and low-risk Ph-negative groups are separated into both age groups. Due to the presence of MRD, higher WBC (as previously noted), or poor genetic analysis, the Ph-negative subgroup may be classed as high-risk.

Conclusion:

The treatment of acute lymphoblastic leukaemia with dose-intensification chemotherapy has been heralded as a remarkable success storey in paediatric oncology. Adult outcomes, on the other hand, are substantially less optimistic because of the disease's high-risk qualities and severe treatment toxicity. Even while some studies have showed that paediatric-inspired regimens are effective, there is still a lot of uncertainty about how to treat adults with acute lymphoblastic leukaemia.

References:

1. Taylor PR, Reid MM, Proctor SJ. Acute lymphoblastic leukaemia in the elderly. Leukemia & lymphoma. 1994 Jan 1;13(5-6):373-80.
2. Delgado-López PD, Corrales-García EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clinical and Translational Oncology. 2016 Nov;18(11):1062-71.
3. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. The Lancet. 2013 Jun 1; 381(9881):1943-55.
4. S.E. Sallan, S. Hitchcock-Bryan, R. Gelber, *et al.* Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia**.** Cancer Res, 43 (1983), pp. 5601-5607

5. H.J. Müller, J. Boos, Use of L-asparaginase in childhood acute lymphoblastic leukemia, Crit Rev Oncol Hematol, 28 (1998), pp. 97-113
6. L.B. Silverman, R.D. Gelber, V.K. Dalton, *et al.* Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium protocol 91-01, Blood, 97 (2001), pp. 1211-1218.
7. S. Gupta, C. Wang, E.A. Raetz, *et al.* Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the children's Oncology Group J Clin Oncol, 38 (2020), pp. 1897-1905.
8. M. Jarrar, P.S. Gaynon, A.P. Periclou, *et al.* Asparagine depletion after PEGylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a children's Oncology Group study (CCG-1941), Pediatr Blood Cancer, 47 (2006), pp. 141-146.
9. Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009; 27: 911–918.
10. Abbafati, C., Machado, D.B., Cislaghi, B.,2019 V., 2020c. Five insights from the Global Burden of Disease Study 2019. The Lancet 396, 1135–1159. https://doi.org/10.1016/S0140-6736(20)31404-5
11. Jameel, P.Z., Lohiya, S., Dongre, A., Damke, S., Lakhkar, B.B., 2020. Concurrent diabetic ketoacidosis and pancreatitis in Paediatric acute lymphoblastic leukemia receiving L-asparaginase. BMC Pediatrics 20. https://doi.org/10.1186/s12887-020-02136-3
12. Raut, N., Mourya, A., Patil, M., 2020. Case report on acute lymphatic leukemia. Indian Journal of Forensic Medicine and Toxicology 14, 6811–6814. https://doi.org/10.37506/ijfmt.v14i4.12691
13. Sharma, P., Gawande, M., Chaudhary, M., Ranka, R., 2018. T-cell lymphoma of oral cavity: A rare entity. Journal of Oral and Maxillofacial Pathology 22, 104–107. https://doi.org/10.4103/jomfp.JOMFP_153_16
14. Vanlalsawmi, J., Mendhe, D., Patil, M., 2020. Thalassemia in children: A case report. Indian Journal of Forensic Medicine and Toxicology 14, 6615–6617. https://doi.org/10.37506/ijfmt.v14i4.12648
15. Chauhan, V.H., Chaudhary, R., Nage, S., 2020. Clinico-haematological profile of children with vitamin B12 deficiency anaemia. Sri Lanka Journal of Child Health 49, 320–324. https://doi.org/10.4038/SLJCH.V49I4.9261